This news release contains certain forward-looking statements relating to STARJEMZA ® /BAT2206 or the product pipelines in general of Bio-Thera Solutions and Hikma. Readers are strongly cautioned that ...

GUANGZHOU, China and LONDON, May 27, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets ...

Please provide your email address to receive an email when new articles are posted on . Imuldosa, an ustekinumab biosimilar, is approved for multiple inflammatory diseases, including Crohn’s disease ...

Johnson & Johnson already has a major presence in the crowded inflammatory bowel disease (IBD) space with its popular Stelara. But with biosimilar versions of the autoimmune blockbuster quickly ...

Celltrion is introducing Steqeymaq (ustekinumab-stba), which is a biosimilar to Johnson & Johnson's Stelara (ustekinumab). Steqeyma is indicated for the treatment of plaque psoriasis and psoriatic ...

Teva Pharmaceuticals and Alvotech announced that the Food and Drug Administration has approved Selarsdi (ustekinumab-aekn) injection as interchangeable with Stelara (ustekinumab). As of April 30, 2025 ...

Imuldosa, a Stelara biosimilar, is approved for autoimmune diseases, marking the fifth ustekinumab biosimilar in the US market. Stelara, a top-grossing biologic, underwent CMS price negotiations with ...